GSK and Theravance announce combination ICS/LABA Phase II results in the Relovair(TM) development programme
GSK and Theravance announce combination ICS/LABA Phase II results in the Relovair(TM) development programme
Sep 22, 2010
Innoviva
Minimum 15 minutes delayed. Source: LSEG
Sign up to receive important email alerts & updates from Innoviva.
Sign up now